Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagida Bibi

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Ebiomedicine|July 2, 2022
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and femalesNatalie Gabrielle Marchevsky, Grace Li, Parvinder Aley, et al.
The Lancet. Microbe|October 2, 2023
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and PolandMaheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, et al.
Frontiers in Immunology|June 9, 2022
Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three CountriesPauline Versteegen, Alex-Mikael Barkoff, Marta Valente Pinto, et al.
Aging Cell|May 22, 2026
Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults-A Pilot StudyGhada Alsaleh, Mohammad Ali, Amir Hossein Kayvanjoo, et al.
The Lancet. Microbe|June 15, 2024
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging studySue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, et al.
Journal of Immunological Methods|October 1, 2024
A novel whole blood assay to quantify the release of T cell associated cytokines in response to Bordetella pertussis antigensMarta Valente Pinto, Alex-Mikael Barkoff, Sagida Bibi, et al.
Ebiomedicine|July 17, 2025
Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222)Sandra Belij-Rammerstorfer, Emma Sheehan, Grace Li, et al.
Lancet (London, England)|June 12, 2022
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trialGrace Li, Federica Cappuccini, Natalie G Marchevsky, et al.
Journal of Clinical Microbiology|March 24, 2022
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCRJeremy Ratcliff, Farah Al-Beidh, Sagida Bibi, et al.
Nature Medicine|October 13, 2022
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infectionAlexander J Mentzer, Daniel O'Connor, Sagida Bibi, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Ebiomedicine|July 2, 2022
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and femalesNatalie Gabrielle Marchevsky, Grace Li, Parvinder Aley, et al.
The Lancet. Microbe|October 2, 2023
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and PolandMaheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, et al.
Frontiers in Immunology|June 9, 2022
Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three CountriesPauline Versteegen, Alex-Mikael Barkoff, Marta Valente Pinto, et al.
Aging Cell|May 22, 2026
Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults-A Pilot StudyGhada Alsaleh, Mohammad Ali, Amir Hossein Kayvanjoo, et al.
The Lancet. Microbe|June 15, 2024
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging studySue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, et al.
Journal of Immunological Methods|October 1, 2024
A novel whole blood assay to quantify the release of T cell associated cytokines in response to Bordetella pertussis antigensMarta Valente Pinto, Alex-Mikael Barkoff, Sagida Bibi, et al.
Ebiomedicine|July 17, 2025
Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222)Sandra Belij-Rammerstorfer, Emma Sheehan, Grace Li, et al.
Lancet (London, England)|June 12, 2022
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trialGrace Li, Federica Cappuccini, Natalie G Marchevsky, et al.
Journal of Clinical Microbiology|March 24, 2022
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCRJeremy Ratcliff, Farah Al-Beidh, Sagida Bibi, et al.
Nature Medicine|October 13, 2022
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infectionAlexander J Mentzer, Daniel O'Connor, Sagida Bibi, et al.
Pageof 6